Fraxiparin solution for injections syringe 0.3 ml. №10

Description

Fraxiparin 0.3 ml Composition
The active ingredient is nadroparin calcium (1 ml of solution contains 9500 anti-Xa nadroparin calcium; 1 pre-filled syringe (0.3 ml) contains 2850 anti-Xa nadroparin calcium).

Excipients: calcium hydroxide solution (or diluted hydrochloric acid), water for injection.

Fraxiparin 0.3 ml Contraindications
Nadroparin is contraindicated in the case of:

hypersensitivity to nadroparin or any of the excipients;
a history of severe heparin-induced thrombocytopenia of type II caused by unfractionated heparin or low molecular weight heparin, as well as a history of nadroparin-induced thrombocytopenia;
episodes of bleeding or a tendency to bleeding associated with hemostasis disorders (disseminated intravascular coagulation may be an exception to this rule, if not associated with heparin treatment);
organic lesions with a risk of bleeding (for example, an active ulcer);
acute disorders of cerebral circulation by hemorrhagic type;
lack of data in severe renal dysfunction (defined creatinine clearance <30 ml / minute according to the Cockcroft formula) in therapeutic doses for the treatment of deep vein thrombosis, thromboembolic events, unstable angina pectoris and myocardial infarction without pathological Q wave, except for use in hemodialysis;
epidural or spinal anesthesia is contraindicated if LMWH is used for treatment;
acute infective endocarditis (with the exception of certain embologenous cardiopathies);
the drug is contraindicated in pediatric patients (under 18 years of age).

Fraxiparin 0.3 ml Mode of application
For subcutaneous use (with the exception of hemodialysis). This dosage form is intended for adults. Do not use for injection.

Subcutaneous injection technique
Do not remove the air bubble from the syringe before injection. Nadroparin is administered by subcutaneous injection, preferably with the patient in a supine position. The drug is injected into the subcutaneous tissue of the anterolateral and posterolateral abdominal walls, alternately on the right and left. The needle should be fully inserted, perpendicularly and not at a different angle, into the fold of skin sandwiched between the performer’s thumb and forefinger. The fold of skin must be held in place during the injection. Since there is a risk of developing HIT, platelet count must be monitored during the entire course of treatment.